The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies

Rheumatology

Volumn 38, Issue SUPPL. 2, 1999, Pages 41-44

  Lipsky, P E ^a   Kavanaugh, A ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cost identification; Cost benefit; Cost effectiveness; DMARD pharmaco economics; Rheumatoid arthritis; Treatment; Tumour necrosis factor alpha

Indexed keywords

ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

CONFERENCE PAPER; COST BENEFIT ANALYSIS; ECONOMIC EVALUATION; FAMILY; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COSTS AND COST ANALYSIS; HUMANS;

EID: 0032738416     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Harris ED. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
2. Sewell KL, Trentham DE. Pathogenesis of rheumatoid arthrits. Lancet 1993;341:283-6.
3. Kavanaugh AF, Lipsky PE. Rheumatoid arthritis. In: Rich RR, Schwartz BD, eds. Clinical immunology: principles and practice, 1st edn. St Louis, MO: Mosby, 1995:1093-116.
4. Felts W, Yelin E. The economic impact of the rheumatic diseases in the United States. J Rheumatol 1989;16:867-84.
5. Fox S, Masi A, Robinson H, Jacob D, Kaplan S. Earnings of early diagnosed arthritis patients and matched controls. J Chron Dis 1976;28:469-78.
6. Reisine S, McQuillan J, Fifield J. Predictors of work disability in rheumatoid arthritis patients. Arthritis Rheum 1995;38:1630-7.
7. Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis: a patient-oriented study of chronic disease costs. Arthritis Rheum 1978;21:827-33.
8. Liang MH, Larson M, Thompson M et al. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984;27:522-9.
9. Jacobs J, Keyserling J, Britton M, Morgan G, Wilkenfeld J, Hutchings H. The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: the Medi-Cal program. J Clin Epidemiol 1988;41:215-23.
10. Lubeck D, Spitz P, Fries J, Wolfe F, Mitchell D, Roth S. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986; 29:488-93.
11. Callahan L, Pincus T. Mortality in the rheumatic diseases. Arthritis Care Res 1995;8:229-41.
12. Kushner I. Does aggressive therapy of rheumatoid arthritis affect outcome? J Rheumatol 1989;16:1-4.
13. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity trade-offs to select second-line drugs in RA. Arthritis Rheum 1992;35:1117-25.
14. Kavanaugh AF, Lipsky PE. The application of biotechnological advances to the treatment of rheumatoid arthritis. In: Wolfe F, Pincus T, eds. Rheumatoid arthritis: pathogenesis, assessment, outcome, and treatment, 1st edn. New York: Marcel Dekker, 1994:373-401.
15. Cush JJ, Kavanaugh AF. Biological interventions in rheumatoid arthritis. Rheum Dis Clin N Am 1995;21: 797-816.
16. Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:693-714.
17. Kavanaugh A, Lipsky P. Inhibitors of TNF-α as therapeutic agents in rheumatoid arthritis. J Musculoskel Med 1998; 15:33-41.
18. Kavanaugh A, Heudebert G, Jain R, Cush J. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 1996;25:297-307.
19. Rice DP. Cost-of-illness studies: fact or fiction? Lancet 1994;344:1519-20.
20. Prashker M. Health care research and policy studies. Curr Opin Rheum 1994;6:140-6.
21. Eisenberg J. Clinical economics. J Am Med Assoc 1989; 262:2879-86.
22. O'Brien B. Principles of economic evaluation for health care programs. J Rheumatol 1995;22:1399-402.
23. Russell L, Gold M, Siegel, Daniels N, Weinstein M. The role of cost-effectiveness analysis in health and medicine. J Am Med Assoc 1996;276:1172-7.
24. Praskher MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995; 38:318-25.
25. Gray A, Marshall M, Lockwood A, Morris J. Problems in conducting economic evaluations alongside clinical trials. Br J Psychiatr 1997;170:47-52.